MAPK1 and melanoma: Therefore, the selective inhibition of BRAF in NRAS mutant melanomas is not an adequate approach, as it can induce the paradoxical activation of RAF proteins and the concomitant ablation of BRAF and CRAF, leading to the emergence of resistant cells showing the ARAF-dependent reactivation of ERK [94].